Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 3/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 5/20 | 0.34 |
| ▸ | JAK1 | P23458 | 5/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30386185 | 0.92 | PTK6 (0.40) | PTK6LCK | |
| SCHEMBL28982185 | 0.92 | PTK6 (0.39) | PTK6TBK1NR1H2NR1H3JAK2 | |
| SCHEMBL30171624 | 0.90 | PTK6 (0.44) | PTK6LCK | |
| SCHEMBL22123122 | 0.90 | PTK6 (0.44) | PTK6LCK | |
| SCHEMBL25450726 | 0.89 | PTK6 (0.38) | PTK6LCK | |
| SCHEMBL24112356 | 0.87 | PTK6 (0.38) | PTK6LCK | |
| SCHEMBL25173551 | 0.86 | GPR119 (0.38) | PTK6TBK1GPR119JAK2JAK1 | |
| Trifluoroacetic Acid SCHEMBL28982207 | 0.86 | PTK6 (0.36) | PTK6 | |
| SCHEMBL30385489 | 0.84 | PTK6 (0.41) | PTK6TBK1NR1H2NR1H3JAK2 | |
| SCHEMBL24112346 | 0.83 | PTK6 (0.39) | PTK6EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4161931-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-4161931-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115916784-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2023-04-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885TBK1 555/4885GPR119 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.